Polymorphic forms of RAD1901-2HCl

1. A solid form of RAD1901-2HCl having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at 11.53 degrees 2θ±0.2 degree 2θ, and at least four peaks, in terms of 2-theta, selected from the group consisting of 22.63 degrees 2θ±0.2 degree 2θ, 14.04 degrees 2θ±0.2 degree 2θ, 19.23 degrees 2θ±0.2 degree 2θ, 26.84 degrees 2θ±0.2 degree 2θ, 8.94 degrees 2θ±0.2 degree 2θ, and 22.39 degrees 2θ±0.2 degree 2θ, at about relative humidity 0% and having a differential scanning calorimetry (DSC) thermogram comprising a melting onset at 210.3° C. and an endothermic peak at 233.8° C.

2. The solid form of claim 1 , having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at 11.53 degrees 2θ±0.2 degree 2θ, and further comprising at least five peaks, in terms of 2-theta, selected from the group consisting of 22.63 degrees 2θ±0.2 degree 2θ, 14.04 degrees 2θ±0.2 degree 2θ, 19.23 degrees 2θ±0.2 degree 2θ, 26.84 degrees 2θ±0.2 degree 2θ, 8.94 degrees 2θ±0.2 degree 2θ, 22.39 degrees 2θ±0.2 degree 2θ, and 24.80 degrees 2θ±0.2 degree 2θ, at about relative humidity 0%.

3. The solid form of claim 1 , having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at 11.53 degrees 2θ±0.2 degree 2θ, and further comprising at least five peaks, in terms of 2-theta, selected from the group consisting of 22.63 degrees 2θ±0.2 degree 2θ, 14.04 degrees 2θ±0.2 degree 2θ, 19.23 degrees 2θ±0.2 degree 2θ, 26.84 degrees 2θ±0.2 degree 2θ, 8.94 degrees 2θ±0.2 degree 2θ, 22.39 degrees 2θ±0.2 degree 2θ, 24.80 degrees 2θ±0.2 degree 2θ, and 25.58 degrees 2θ±0.2 degree 2θ, at about relative humidity 0%.

4. The solid form of claim 1 , having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at 11.53 degrees 2θ±0.2 degree 2θ, and further comprising at least six peaks, in terms of 2-theta, selected from the group consisting of 22.63 degrees 2θ±0.2 degree 2θ, 14.04 degrees 2θ±0.2 degree 2θ, 19.23 degrees 2θ±0.2 degree 2θ, 26.84 degrees 2θ±0.2 degree 2θ, 8.94 degrees 2θ±0.2 degree 2θ, 22.39 degrees 2θ±0.2 degree 2θ, 24.80 degrees 2θ±0.2 degree 2θ, 25.58 degrees 2θ±0.2 degree 2θ, and 21.66 degrees 2θ±0.2 degree 2θ, at about relative humidity 0%.

5. The solid form of claim 1 , having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at 11.53 degrees 2θ±0.2 degree 2θ, and further comprising at least seven peaks, in terms of 2-theta, selected from the group consisting of 22.63 degrees 2θ±0.2 degree 2θ, 14.04 degrees 2θ±0.2 degree 2θ, 19.23 degrees 2θ±0.2 degree 2θ, 26.84 degrees 2θ±0.2 degree 2θ, 8.94 degrees 2θ±0.2 degree 2θ, 22.39 degrees 2θ±0.2 degree 2θ, 24.80 degrees 2θ±0.2 degree 2θ, 25.58 degrees 2θ±0.2 degree 2θ, 21.66 degrees 2θ±0.2 degree 2θ, and 28.76 degrees 2θ±0.2 degree 2θ, at about relative humidity 0%.

6. The solid form of claim 1 , having an X-ray powder diffraction pattern comprising the peaks, in terms of 2-theta, of 8.94 degrees 2θ±0.2 degree 2θ, 11.53 degrees 2θ±0.2 degree 2θ, 14.04 degrees 2θ±0.2 degree 2θ, 19.23 degrees 2θ±0.2 degree 2θ, 21.66 degrees 2θ±0.2 degree 2θ, 22.39 degrees 2θ±0.2 degree 2θ, 22.63 degrees 2θ±0.2 degree 2θ, 24.80 degrees 2θ±0.2 degree 2θ, 25.58 degrees 2θ±0.2 degree 2θ, 26.84 degrees 2θ±0.2 degree 2θ, and 28.76 degrees 2θ±0.2 degree 2θ, at about relative humidity 0%.

7. The solid form of claim 1 , having an X-ray powder diffraction pattern as shown in FIG. 22 C at about relative humidity 0%.

8. The solid form of claim 1 , having a thermogravimetric analysis (TGA) thermogram as shown in the top of FIG. 21 A .

9. A pharmaceutical composition comprising the solid form of claim 1 and one or more pharmaceutically acceptable excipients.

10. The solid form of claim 1 , having a 13 C solid-state CPMAS NMR pattern as shown for Pattern B in FIG. 23 , a 1 H solid-state MAS NMR pattern as shown for Pattern B in FIG. 24 , an FT-IR pattern as shown in FIG. 25 C , and a Raman Spectroscopy pattern as shown for Pattern B in FIG. 26 .

11. A process for preparing the solid form of claim 1 comprising precipitating from a solution comprising RAD1901-2HCl and a solvent, or slurring RAD1901-2HCl in a solvent, wherein the solvent comprises an organic solvent selected from the group consisting of 2-ethoxyethanol, 1,2-dichloroethane, and ethyl acetate, and the content of water is at or below 5% v/v and isolating the solid form of claim 1 .

12. A method of treating breast cancer or ovarian cancer, comprising an administration to a subject in need thereof the solid form of RAD1901-2HCl as described in claim 1 .

13. The method of claim 12 wherein said breast cancer is positive for the estrogen receptor.